Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study
European Journal of Cancer2021Vol. 146, pp. 107–114
Citations Over TimeTop 10% of 2021 papers
Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, Oliver G. Ottmann, Nicola Gökbuget, Alessandro Rambaldi, Ellen K. Ritchie, Cristina Papayannidis, Catherine Tuglus, Joan Morris, Anthony S. Stein
Abstract
Long-term durability of responses to blinatumomab was demonstrated in patients with R/R Ph+ ALL.
Related Papers
- → Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date(2018)23 cited
- → Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab(2016)7 cited
- → EE289 Cost-Effectiveness Analysis of Blinatumomab for Advanced Acute Lymphoblastic Leukemia in Japan(2024)1 cited
- → Results of Salvage Therapy with Mini-Hyper-CVD and Inotuzumab Ozogamicin with or Without Blinatumomab in Pre-B Acute Lymphoblastic Leukemia(2022)5 cited
- → Blinatumomab for hard-to-treat form of acute lymphoblastic leukemia(2015)